Corvus Pharmaceuticals (CRVS) Competitors $4.26 +0.01 (+0.24%) Closing price 04:00 PM EasternExtended Trading$4.25 -0.01 (-0.33%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUSShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Enliven Therapeutics Structure Therapeutics Cidara Therapeutics Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Corvus Pharmaceuticals (NASDAQ:CRVS) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has more volatility & risk, CRVS or ELVN? Corvus Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Is CRVS or ELVN more profitable? Corvus Pharmaceuticals' return on equity of -24.04% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -24.04% -13.90% Enliven Therapeutics N/A -31.84%-30.09% Which has stronger earnings & valuation, CRVS or ELVN? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.35Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80 Does the media prefer CRVS or ELVN? In the previous week, Enliven Therapeutics had 6 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Enliven Therapeutics and 0 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Enliven Therapeutics' score of 0.71 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Enliven Therapeutics Positive Do analysts recommend CRVS or ELVN? Corvus Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 252.11%. Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 81.82%. Given Corvus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of CRVS or ELVN? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCorvus Pharmaceuticals beats Enliven Therapeutics on 7 of the 11 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.72M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-4.358.2821.0120.09Price / SalesN/A303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book8.357.678.125.65Net Income-$62.29M-$55.28M$3.25B$257.91M7 Day Performance2.90%2.50%0.97%2.09%1 Month Performance8.40%11.70%7.36%11.13%1 Year Performance99.07%4.89%31.31%18.40% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.8841 of 5 stars$4.26+0.2%$15.00+252.1%+95.9%$289.72MN/A-4.3530Positive NewsELVNEnliven Therapeutics2.8636 of 5 stars$23.00+2.4%$41.20+79.1%-1.8%$1.13BN/A-11.9850News CoverageGPCRStructure Therapeutics2.9436 of 5 stars$19.57+2.9%$76.17+289.2%-49.1%$1.12BN/A-22.49136CDTXCidara Therapeutics3.6939 of 5 stars$55.32+9.5%$57.29+3.6%+331.6%$1.12B$1.27M-1.8890Positive NewsHigh Trading VolumeARDXArdelyx4.1637 of 5 stars$4.61+2.7%$10.89+136.2%-21.4%$1.10B$333.61M-20.9590Analyst RevisionPRAXPraxis Precision Medicines2.4592 of 5 stars$53.60+6.1%$94.11+75.6%-0.3%$1.09B$8.55M-5.00110News CoverageAnalyst ForecastAnalyst RevisionPROKProKidney3.4049 of 5 stars$3.69-18.7%$5.67+53.6%+53.0%$1.08B$306K-6.153Analyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.4186 of 5 stars$32.83+1.0%$43.75+33.3%+1.0%$1.05B$631.45M26.91210Positive NewsAKBAAkebia Therapeutics3.7148 of 5 stars$3.97+1.0%$6.75+70.0%+175.2%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.3171 of 5 stars$21.95+1.3%$32.33+47.3%-45.0%$1.03B$731.97M7.952,028RCUSArcus Biosciences2.3406 of 5 stars$9.66+3.5%$21.29+120.5%-39.0%$1.02B$258M-2.30500 Related Companies and Tools Related Companies Enliven Therapeutics Alternatives Structure Therapeutics Alternatives Cidara Therapeutics Alternatives Ardelyx Alternatives Praxis Precision Medicines Alternatives ProKidney Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts